Skip to search formSkip to main contentSkip to account menu

olprinone

Known as: 1,2-dihydro-6-methyl-2-oxo-5-(imidazo(1,2-a)pyridin-6-yl)-3-pyridinecarbonitrile 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Endothelial barrier function is an essential and tightly regulated process that ensures proper compartmentalization of the… 
2012
2012
Olprinone, a specific phosphodiesterase III inhibitor, and corforsin daropate, a direct adenylate cyclase activator, are now… 
Review
2006
Review
2006
Olprinone is a newly developed phosphodiesterase III inhibitor characterized by several properties. First, olprinone has positive… 
2003
2003
Cerebral blood flow (CBF) is reduced in heart failure (HF). For the treatment of acute HF, a phosphodiesterase-3 inhibitor… 
2003
2003
AIMS There is no evidence demonstrating the clinical usefulness of phosphodiesterase (PDE) inhibitors in the treatment of asthma… 
Highly Cited
2001
Highly Cited
2001
Background—Phosphodiesterase III inhibitors (PDEIII-Is) improve the hemodynamic status of heart failure via inotropic… 
2001
2001
IV aminophylline, a nonselective phosphodiesterase (PDE) inhibitor, is often used to treat an asthma attack during anesthesia… 
2000
2000
Objective: To measure the hepatic venous oxygen saturation in patients after cardiac surgery and to compare the effects of… 
2000
2000
Background: Increasing evidence indicates that amrinone, a phosphodiesterase fraction III (PDE‐III) inhibitor, has relative… 
Highly Cited
1999
Highly Cited
1999
The effect of topical administration of phosphodiesterase (PDE) 3 inhibitors on the airway is not clear. In order to examine the…